卡氮介脂质体后续给药法治疗肺癌脑转移瘤的临床研究  

BL for the treatment of brain metastasis lung cancer

作　　者：李明 姜俊阁 

机构地区：[1]大连市第五人民医院肿瘤科,116020 [2]大连市胸科肿瘤医院肿瘤科

出　　处：《中国医师进修杂志（内科版）》2006年第6期26-27,共2页Chinese Journal of Postgraduates of Medicine

摘　　要：目的探讨卡氮介(BCNU)和卡氮介脂质体(BL)治疗肺癌脑转移的疗效及毒性反应,评价后续给药法在疗效、毒性反应的作用。方法将60例经病理检查证实及脑CT确诊的肺癌脑转移患者随机分为BL组(30例)和BCNU组(30例)。BL组:后续法应用BL治疗,BCNU组:采用常规给药治疗。结果BL组脑转移患者生存期优于BCNU组(P<0.05),两组治疗方法对脑转移患者的有效率差异无统计学意义(P>0.05),血液毒性反应发生率BL组低于BCNU组,生存质量BL组高于BCNU组(P<0.05)。结论BL后续给药法在患者生存期、生存质量、毒性反应发生率均优于常规法BCNU的治疗。Objective To evaluate and compare effects the BL or BCNU for the treatment of brain metastasis cell lung cancer. Methods Sixty cases with brain metastasis lung cancer diagnosed by pathologic, cytologic and CT examination were enrolled divided into BL groups and BCNU groups. Results There were no significant different in the response of rate for tow groups （ P 〉 0.05）. WHO grade Ⅲ/Ⅳ neutropenia 10%in BL groups,47% in BCNU groups. The BL groups was longer than BCNU groups in survival time（P 〈 0.05）. Conclusion BL and BCNU have similar effective rate, but in the survival time, BL is longer than BCNU. In the quality of life, BL is better than BCNU. BL might be better chemotherapeutic regiment for brain metastasis lung cancer.

关 键 词：卡氮介脂质体 卡氮介 肺癌 脑转移 化疗 

分 类 号：R739.410.5[医药卫生—肿瘤] R274.915.3[医药卫生—临床医学]